GlassScriptPhysician profile
James A Lamar
NPI 1346654126
$44,743.33
in general payments reported to CMS, 2019-2025
23 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,666 · 2020: $266 · 2021: $1,038 · 2022: $1,125 · 2023: $2,843 · 2024: $1,325 · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Food and Beverage: $5,492 · Travel and Lodging: $4,429 · Entertainment: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,350.00 |
| Food and Beverage | $5,492.46 |
| Travel and Lodging | $4,428.84 |
| Entertainment | $378.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $37,089.90 | 2022-2025 | |
| Alcon Vision LLC | $2,328.33 | 2019-2025 | Total30, Precision7, Precision 1 |
| Optos, INC. | $826.77 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $674.91 | 2019-2025 | Idose, Photrexa Viscous and Photrexa, Iaccess Precision Blade |
| Allergan, INC. | $488.63 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $402.21 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $397.42 | 2020-2025 | Acuvue |
| Abbvie INC. | $334.41 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $303.91 | 2020-2023 | |
| Dompe US, INC. | $293.22 | 2023-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $276.07 | 2024-2025 | Acthar |
| Oyster Point Pharma, INC. | $249.58 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $197.37 | 2023-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $149.79 | 2020-2024 | One Series Ultra |
| Coopervision INC. | $149.47 | 2022-2024 | Biofinity Contact Lens, Misight Contact Lens, Clariti Contact Lens |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $149.25 | 2022-2025 | Xiidra, Miebo |
| Carl Zeiss Meditec USA, INC. | $132.34 | 2023 | Clarus |
| Alimera Sciences, INC. | $93.85 | 2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $76.52 | 2024 | Syfovre |
| Harrow Eye, LLC | $46.13 | 2024 | Natacyn, Verkazia, Tobradex St |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.52 | 2019-2020 | |
| Ocular Therapeutix, INC. | $28.84 | 2023 | Dextenza |
| Eyevance Pharmaceuticals LLC | $19.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.